Vaughan Nelson Investment Management L.P. Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Vaughan Nelson Investment Management L.P. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 5.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 679,397 shares of the company’s stock after selling 41,174 shares during the quarter. Johnson & Johnson accounts for 1.1% of Vaughan Nelson Investment Management L.P.’s portfolio, making the stock its 27th largest position. Vaughan Nelson Investment Management L.P.’s holdings in Johnson & Johnson were worth $106,488,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Hibernia Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth $27,000. FNY Investment Advisers LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth $37,000. Tower View Wealth Management LLC grew its stake in shares of Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares in the last quarter. Creative Capital Management Investments LLC grew its stake in shares of Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth about $48,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.9 %

JNJ stock opened at $148.78 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The company has a market cap of $358.53 billion, a price-to-earnings ratio of 10.77, a price-to-earnings-growth ratio of 2.55 and a beta of 0.53. The company has a fifty day moving average price of $157.42 and a 200 day moving average price of $156.08. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. Johnson & Johnson’s revenue was down 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.35 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Raymond James lifted their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $177.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.